# A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Source: https://onco.cc/trials/nct06908304/  
OnCo record `nct06908304` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cemiplimab, Docetaxel, Vinorelbine and Gemcitabine in non-small-cell lung cancer, run by Maia Biotechnology, now recruiting.

## Summary

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC is a phase 3 interventional study registered as NCT06908304 by Maia Biotechnology, with 300 participants planned, started 2025-12-08 and due to reach its primary completion in 2027-07-31. Interventions recorded: 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel, Vinorelbine and Gemcitabine alone.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06908304
- Phase: 3
- Setting: A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs Investigator's Choice of Chemotherapy as Third-line Treatment in Advanced/Metastatic NSCLC
- Sponsor: Maia Biotechnology
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT06908304: https://clinicaltrials.gov/study/NCT06908304

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Vinorelbine](https://onco.cc/drugs/vinorelbine/)
- companies: [Maia Biotechnology](https://onco.cc/companies/maia-biotechnology/)

---
JSON: https://onco.cc/api/v1/entities/nct06908304.json